Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 8/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.47 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.47 |
| ▸ | CTSV | O60911 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4395583 | 0.94 | NPC1 (0.55) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL3260635 | 0.94 | NPC1 (0.55) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL12664955 | 0.91 | RAB9A (0.48) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL4929503 | 0.89 | KMT2A (0.58) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL3172396 | 0.88 | ALK (0.50) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL1894480 | 0.88 | MEN1 (0.52) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL1898323 | 0.87 | RAB9A (0.46) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL4062637 | 0.85 | RAB9A (0.43) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL4345309 | 0.83 | EGFR (0.47) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL3182550 | 0.81 | MEN1 (0.66) | NPC1RAB9AMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652022-B2 | N-(4-(4-(4-hydroxyphenylamino)-pyrimidin-6-yl)-oxyphenyl)-N'-(3-trifluoromethylphenyl)-urea; | NOVARTIS AG (CH) | 2010-01-26 | — | — | US | disclosed |
| EP-1511730-B8 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-20060128734-A1 | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | FLOERSHEIMER ANDREAS | 2006-06-15 | — | — | US | disclosed |
| EP-1511730-A2 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003099771-A2 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128734-A1 | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | UCK2, PRKDC, PRKACA | NPC1 2696/4885RAB9A 1414/4885MEN1 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.